锚定系链『受阻』HCN1抑制剂在大鼠 spared nerve injury 神经病理性疼痛模型中具有抗痛觉过敏作用
研究通过分子动力学模拟、体外电生理和大鼠 spared nerve injury 模型,测试对2,6-二叔丁基苯酚(26DTB-P)进行『受阻』修饰的变体是否具有HCN1选择性抗痛觉过敏作用且不穿透血脑屏障。结果显示BP4L-18:1:1(经18碳系链连接二醇锚的变体)为HCN1反向激动剂和口服抗痛觉过敏药,CNS多参数优化评分2.25,脑/血药物负荷比>100倍,无心血管或CNS不良反应,证明锚定系链药物是治疗膜靶点相关疾病的新化学型。
要点
- BP4L-18:1:1是口服有效的HCN1反向激动剂,在大鼠SNI模型中抗痛觉过敏。
- 该药脑/血药物负荷比>100倍,CNS穿透性低且不累及心脏亚型。
- 未观察到心血管或中枢神经系统不良反应。
核心结论
- 锚定系链药物是治疗膜靶点相关疾病的新化学型,BP4L-18:1:1概念验证成功。
研究设计与样本
- 采用计算机分子动力学模拟、体外电生理和大鼠spared nerve injury神经病理性疼痛模型进行测试。
主要发现
- 分子动力学模拟显示受阻26DTB-P的膜穿透受系链二醇锚控制,且不消除头基旋转自由度。
- BP4L-18:1:1是HCN1反向激动剂和口服抗痛觉过敏药,CNS多参数优化评分为2.25。
- BP4L-18:1:1脑/血药物负荷比>100倍,无心血管或CNS不良反应,CNS穿透性低且心脏 sparing。
关键数值与推荐
- BP4L-18:1:1的CNS多参数优化评分为2.25。
- BP4L-18:1:1脑/血药物负荷比>100倍。
临床怎么用
- 提示锚定系链HCN1抑制剂可能作为不穿透血脑屏障、心脏安全的抗痛觉过敏药物开发。
局限性
- 研究仅在大鼠模型中进行,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neuropathic pain impairs quality of life, is widely prevalent, and incurs significant costs. Current pharmacological therapies have poor/no efficacy and significant adverse effects; safe and effective alternatives are needed. Hyperpolarisation-activated cyclic nucleotide-regulated (HCN) channels are causally implicated in some forms of peripherally mediated neuropathic pain. Whilst 2,6-substituted phenols, such as 2,6-di-tert-butylphenol (26DTB-P), selectively inhibit HCN1 gating and are antihyperalgesic, the development of therapeutically tolerable, HCN-selective antihyperalgesics based on their inverse agonist activity requires that such drugs spare the cardiac isoforms and do not cross the blood-brain barrier. METHODS: In silico molecular dynamics simulation, in vitro electrophysiology, and in vivo rat spared nerve injury methods were used to test whether 'hindered' variants of 26DTB-P (wherein a hydrophilic 'anchor' is attached in the para-position of 26DTB-P via an acyl chain 'tether') had the desired properties. RESULTS: Molecular dynamics simulation showed that membrane penetration of hindered 26DTB-Ps is controlled by a tethered diol anchor without elimination of head group rotational freedom. In vitro and in vivo analysis showed that BP4L-18:1:1, a variant wherein a diol anchor is attached to 26DTB-P via an 18-carbon tether, is an HCN1 inverse agonist and an orally available antihyperalgesic. With a CNS multiparameter optimisation score of 2.25, a >100-fold lower drug load in the brain vs blood, and an absence of adverse cardiovascular or CNS effects, BP4L-18:1:1 was shown to be poorly CNS penetrant and cardiac sparing. CONCLUSIONS: These findings provide a proof-of-concept demonstration that anchor-tethered drugs are a new chemotype for treatment of disorders involving membrane targets.
引用
- Tibbs GR, Uprety R, Warren JD, et al. An anchor-tether 'hindered' HCN1 inhibitor is antihyperalgesic in a rat spared nerve injury neuropathic pain model. Br J Anaesth. 2023. PMID: 37567808. doi:10.1016/j.bja.2023.06.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。